What’s new

• Management cut FY27 revenue growth guidance to 15% from 20% due to Middle East supply chain disruptions.
• The company pivoted resources from anti-diabetic drugs to higher-margin ARV and anti-inflammatory APIs.
• Backward integration into Ibuprofen now accounts for 20% of revenue, shielding margins from cost spikes.

Why it matters

The guidance cut is a direct reaction to external volatility, yet the shift toward specialized API segments suggests a defensive strategy to maintain margins. Investors should watch whether the Rs 280 crore capex program can deliver the promised high-margin product mix by FY28.

What we’re watching

• Whether the external environment stabilizes to allow a return to 20-25% growth.
• Execution of the Rs 280 crore capex plan for new API capacity.
• Progress on the goal to reach 60% revenue contribution from high-value APIs.

The full read

SMS Pharmaceuticals reported a 13% revenue rise to Rs 887 crore for FY26 with EBITDA margins of 20%.

Growth is slowing.

Management lowered its FY27 revenue growth guidance to 15% from 20%, citing geopolitical disruptions in the Middle East that are currently snarling supply chains. To counter these pressures, the company is pivoting away from its anti-diabetic segment to focus on ARV and anti-inflammatory APIs, while backward integration into Ibuprofen intermediates now accounts for 20% of revenue to provide a buffer against recent cost volatility. Looking ahead, management targets an EBITDA margin of 22% for FY27, supported by a Rs 280 crore capex program that is set to introduce new high-margin APIs starting in FY28. While the guidance cut reflects immediate external risks, the company is betting that its product-mix shift and vertical integration will sustain profitability through a difficult period.

Primary source: BSE · NSE

What’s new

• Standalone revenue hit ₹886.87 cr, rising 13.3% from the prior year.
• The board declared a final dividend of ₹0.40 per share.
• Administrative updates include a change in registered office and auditor appointments.

Why it matters

The company met the expectations set in its previous quarterly updates. With no material surprises, this release confirms a steady performance trajectory.

What we’re watching

• Sustainability of current profit margins.
• Product mix shifts in the new fiscal year.
• Execution of capacity expansion.

The full read

SMS Pharmaceuticals closed the fiscal year with ₹886.87 crore in standalone revenue and ₹87.61 crore in net profit. These figures mark a 13.3% and 28.1% increase over the previous year. The board recommended a final dividend of ₹0.40 per share, accompanied by routine administrative changes such as an auditor appointment and an office relocation. This disclosure contains no surprises. It confirms the growth trends outlined in the company’s earlier quarterly reports. The open question is whether these margins persist in the coming year. What changes from here is the company's ability to maintain this pace as it scales production.

Primary source: BSE · NSE

What’s new

• Standalone revenue hit ₹886.87 cr, a 13.3% increase over the previous year.
• Net profit reached ₹87.61 cr, up 28.1% year-on-year.
• Board approved a final dividend of ₹0.40 per share.

Why it matters

Performance matches the prior quarterly guidance exactly. There are no surprises here.

What we’re watching

• Margin consistency in upcoming quarterly filings.
• Capital allocation plans following the modest dividend payout.
• Stability of the new auditor's oversight.

The full read

SMS Pharmaceuticals closed FY26 with standalone revenue of ₹886.87 crore, a 13.3% increase from the prior year. Net profit grew by 28.1% to reach ₹87.61 crore. These figures land exactly where the company’s previous quarterly updates suggested they would.

No surprises.

The board approved a modest final dividend of ₹0.40 per share while confirming an unmodified audit opinion. Other changes, such as moving the registered office and appointing new auditors, fall under standard administrative maintenance. The open question is whether the company can maintain this growth pace in FY27 without the tailwinds seen in this reporting cycle. For now, the story remains one of steady, guided execution.

Primary source: BSE · NSE

What’s new

• Standalone revenue rose 13.3% YoY to ₹886.87 cr.
• Net profit climbed 28.1% to ₹87.61 cr.
• The board proposed a final dividend of ₹0.40 per share.

Why it matters

The company delivered growth in line with expectations. There are no surprises here, just standard operational performance confirmed by an unmodified audit opinion.

What we’re watching

• Future capacity utilization updates.
• Updates on the office shift logistics.
• Any material deviation in quarterly margins.

The full read

SMS Pharmaceuticals posted its FY26 audited results, confirming a year of consistent, anticipated growth. Standalone revenue hit ₹886.87 crore, a 13.3% increase over the previous year, while net profit rose more sharply by 28.1% to reach ₹87.61 crore. The board declared a final dividend of ₹0.40 per share, maintaining a conservative payout profile. With an unmodified audit opinion and standard administrative updates regarding office shifts and auditor appointments, the filing adds no new tactical information to the company's existing trajectory. It is a clean, routine disclosure of financial performance that mirrors the market's expected baseline.

Primary source: BSE · NSE

What’s new

• FY26 standalone net profit rose 28.1% to ₹87.61 crore on revenue of ₹886.87 crore.
• Board recommends a final dividend of ₹0.40 per share.
• Annual results were disclosed after quarterly updates were already in the public domain.

Why it matters

The numbers themselves are solid: a 28% profit increase on 13.3% revenue growth points to margin improvement. But the results were largely telegraphed by the quarterly disclosures, so the annual filing adds little new information for the market to digest. The dividend is negligible.

What we’re watching

• Whether the margin improvement holds in FY27 as revenue scales.
• The board's next move on capital allocation given the modest payout.
• Any commentary on capacity or demand trends from the annual report.

The full read

SMS Pharmaceuticals' FY26 annual results confirm a 28.1% jump in net profit to ₹87.61 crore, driven by 13.3% revenue growth to ₹886.87 crore. The growth profile is clean, with profits outpacing revenue, which points to better cost control. But the filing itself is routine. The quarterly results that comprise these annual figures have already been disclosed, so the market is not learning anything new. The board also recommended a final dividend of ₹0.40 per share, a negligible payout that signals the company is hoarding cash for now rather than rewarding shareholders directly.

Primary source: BSE · NSE